Abbvie Inc (NYSE: ABBV) has experienced a decline in its stock price by -2.74 compared to its previous closing price of 169.63. However, the company has seen a fall of -17.30% in its stock price over the last five trading days. 247wallst.com reported 2024-11-17 that Pharmaceutical giant AbbVie (NYSE:ABBV) has suffered a meltdown over the past week, with shares losing 15% of their value.
Is It Worth Investing in Abbvie Inc (NYSE: ABBV) Right Now?
The price-to-earnings ratio for Abbvie Inc (NYSE: ABBV) is above average at 57.54x, Company’s 36-month beta value is 0.56.Analysts have differing opinions on the stock, with 12 analysts rating it as a “buy,” 9 as “overweight,” 10 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ABBV is 1.77B, and currently, short sellers hold a 1.03% ratio of that floaft. The average trading volume of ABBV on November 18, 2024 was 5.18M shares.
ABBV’s Market Performance
The stock of Abbvie Inc (ABBV) has seen a -17.30% decrease in the past week, with a -12.50% drop in the past month, and a -16.19% fall in the past quarter. The volatility ratio for the week is 2.64%, and the volatility levels for the past 30 days are at 2.13% for ABBV. The simple moving average for the past 20 days is -12.76% for ABBV’s stock, with a -7.79% simple moving average for the past 200 days.
Analysts’ Opinion of ABBV
Many brokerage firms have already submitted their reports for ABBV stocks, with Wolfe Research repeating the rating for ABBV by listing it as a “Outperform.” The predicted price for ABBV in the upcoming period, according to Wolfe Research is $205 based on the research report published on November 15, 2024 of the current year 2024.
Bernstein gave a rating of “Mkt Perform” to ABBV, setting the target price at $203 in the report published on October 17th of the current year.
ABBV Trading at -14.09% from the 50-Day Moving Average
After a stumble in the market that brought ABBV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.42% of loss for the given period.
Volatility was left at 2.13%, however, over the last 30 days, the volatility rate increased by 2.64%, as shares sank -12.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.69% lower at present.
During the last 5 trading sessions, ABBV fell by -17.30%, which changed the moving average for the period of 200-days by -1.55% in comparison to the 20-day moving average, which settled at $189.13. In addition, Abbvie Inc saw 6.47% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABBV starting from Hudson Thomas J, who proposed sale 49,170 shares at the price of $189.08 back on Aug 08 ’24. After this action, Hudson Thomas J now owns shares of Abbvie Inc, valued at $9,297,210 using the latest closing price.
GONZALEZ RICHARD A, the EXECUTIVE CHAIRMAN OF BOARD of Abbvie Inc, sale 66,500 shares at $186.52 during a trade that took place back on Aug 05 ’24, which means that GONZALEZ RICHARD A is holding 446,599 shares at $12,403,580 based on the most recent closing price.
Stock Fundamentals for ABBV
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.77 for the gross margin
The net margin for Abbvie Inc stands at 0.09. The total capital return value is set at 0.14. Equity return is now at value 56.06, with 3.63 for asset returns.
Based on Abbvie Inc (ABBV), the company’s capital structure generated 0.92 points at debt to capital in total, while cash flow to debt ratio is standing at 0.23. The debt to equity ratio resting at 11.78. The interest coverage ratio of the stock is 5.44.
Currently, EBITDA for the company is 26.36 billion with net debt to EBITDA at 2.5. When we switch over and look at the enterprise to sales, we see a ratio of 6.4. The receivables turnover for the company is 4.84for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.65.
Conclusion
In a nutshell, Abbvie Inc (ABBV) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
